Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TCT 2018: Medtronic's CoreValve Proves Durable Out To Five Years

Executive Summary

The five-year results from the US pivotal high-risk trial of Medtronic's CoreValve transcatheter aortic valve, the longest-term follow-up data from a randomized trial of CoreValve, show the valve remains durable with low rates of severe hemodynamic structural valve deterioration compared to surgical valves.

You may also be interested in...

US FDA Green-Lights Medtronic's CoreValve Evolut For Intermediate Risk

The approval, based on the results of the SURTAVI trial, comes a few months ahead of analysts' expectations and is welcome news for Medtronic in its effort to keep pace with TAVR leader Edwards in the US market.

ACC 2016 BEST OF THE REST: Surgery Trials, More CoreValve Data, Leadless Pacemakers, Drug-Filled Stents, And More

Almost 19,000 people were in Chicago April 2-4 for the 2016 American College of Cardiology's Annual Scientific Sessions, which featured over 2,400 presentations, including 24 late-breaking trials and 10 other clinical research presentations. Edwards’ transcatheter valves grabbed most of the headlines, but here are some of the other highlights from medical device trial results presented at the meeting

Becton Dickinson, BioMedomics Collaborate On Rapid Serology COVID-19 Test

BD and BioMedomics will soon begin distributing a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts